SRRK

Scholar Rock Holding Corp

Nasdaq · Biological Products, (No Diagnostic Substances)

Insider trades

Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Scholar Rock is a biopharmaceutical company developing therapies that target protein growth factor activation, with its lead program apitegromab designed to treat spinal muscular atrophy by selectively inhibiting myostatin activation.

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Cambridge, MA

Exchange

Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

Insider	Type	Value	Shares / Price	Date
AKKARAJU SRINIVASDirector	Buy	$4.08M	97,982at $41.59	Oct 26, 2026
AKKARAJU SRINIVASDirector	Buy	$3.88M	94,000at $41.31	Oct 23, 2026
AKKARAJU SRINIVASDirector	Buy	$2.04M	48,988at $41.59	Oct 26, 2026
AKKARAJU SRINIVASDirector	Buy	$1.94M	47,000at $41.31	Oct 23, 2026
AKKARAJU SRINIVASDirector	Buy	$42K	1,000at $41.82	Oct 23, 2026
AKKARAJU SRINIVASDirector	Buy	$21K	500at $41.82	Oct 23, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for SRRK.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable SRRK activity by email

Free alerts for the insider and congressional trades worth watching.

Email address

US mobile number (optional)

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

By checking this box and submitting, I agree to receive recurring automated marketing text messages from MySmarTrend (Ramy LLC) at the mobile number provided, including market alerts, commentary, and offers for MySmarTrend products and subscriptions. Messages may begin when the SMS program launches. Message frequency varies. Message and data rates may apply. Consent is not a condition of purchase or email signup. Reply STOP to opt out or HELP for help once messaging begins. Before launch or at any time, contact privacy@mysmartrend.com to withdraw consent or get help. I agree to the SMS Terms and acknowledge the Privacy Policy.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.